Acrivon Therapeutics, Inc. Shareholders' Equity
Acrivon Therapeutics, Inc. (ACRV) had Shareholders' Equity of $86.67 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $86.67M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $95.52M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $112.52M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $128.60M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $86.67M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $95.52M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $112.52M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $128.60M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $143.04M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $160.39M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $176.79M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $196.89M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $216.06M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $107.98M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $121.19M 10-K · filed 2026-03-19 |
| 2023-09-30 | $138.15M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $149.18M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $160.47M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $170.47M 10-K · filed 2025-03-27 |
| 2022-09-30 | -$45.62M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$36.58M 10-Q · filed 2023-11-09 |
| 2022-03-31 | -$30.99M 10-Q · filed 2023-11-09 |
| 2021-12-31 | -$23.81M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$19.77M 10-Q · filed 2022-12-15 |
| 2021-06-30 | -$17.36M 10-Q · filed 2022-12-15 |
| 2021-03-31 | -$14.84M 10-Q · filed 2022-12-15 |
| 2020-12-31 | -$8.41M 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |